University of Southern Maine

USM Digital Commons
Thinking Matters Symposium

2020 Thinking Matters Symposium

May 8th, 12:00 AM

Biosynthesis of Cannabinoids in S. cerevisiae
Micah Smith
Southern Maine Community College, micahtsmith@smccme.edu

Follow this and additional works at: https://digitalcommons.usm.maine.edu/thinking-matters-symposium

Smith, Micah, "Biosynthesis of Cannabinoids in S. cerevisiae" (2020). Thinking Matters Symposium. 82.
https://digitalcommons.usm.maine.edu/thinking-matters-symposium/2020/poster-sessions/82

This Poster Session is brought to you for free and open access by the Student Scholarship at USM Digital
Commons. It has been accepted for inclusion in Thinking Matters Symposium by an authorized administrator of
USM Digital Commons. For more information, please contact jessica.c.hovey@maine.edu.

BiosynthesisMicah
ofSmith,
Cannabinoids
in S. cerevisiae
Southern Maine Community College
Abstract:
THC, CBD, and other cannabinoids have modern and historical uses in
medicine. Studying these cannabinoids has been challenging due to the
classification of these substances as narcotics and due to legal issues
surrounding the plant, Cannabis sativa.
This literature review discusses some of the manipulations and modifications
of biosynthetic pathways in Saccharomyces cerevisiae that have been done by
researchers. Genes from Cannabis sativa and other organisms have been
added to yeast so that enzymes are produced to metabolize THC and other
cannabinoids from simple sugars.
Modifying an organism to produce certain chemical substances is more
complex than modifying an organism to code for a particular polypeptide.
Occasionally novel substances not found in nature are produced.
The development of reliable, lab-sustainable production of known and new
biochemicals has great potential.

(Fig. 3, Luo X., et al., 2019)

Introduction:

THC and CBD: The primary active
compounds that produce the psychoactive
and calming effects of Cannabis.

The medicinal uses of Cannabis, also known as
marijuana, have been rediscovered by doctors,
biologists, and health experts across the globe.
As more governments decriminalize and legalize
medical and/or personal use of the plant and its
derived chemical substances, THC and CBD. As
the organism becomes more accessible to
obtain legally, there is an increase in demand for
these substances for research purposes.
The development of new sources of THC, CBD,
and other cannabinoids as research chemicals
requires a means of producing them in the
laboratory environment for manipulation and
study.
A team of scientists genetically modified a strain
of brewer’s yeast (S. cerevisiae) to produce
delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD) as well as novel cannabinoids
that are not naturally occuring in the Cannabis
plant. The development of this pathway not only
allows for the compounds to be produced
without the need of the plant, but also exists as a
means to modify the existing pathways in the
plant to produce the new cannabinoids in higher
quantity and quality.

Cannabinoid production via artificially-created biosynthetic
pathways in yeast currently faces a problem with yield of the
desired substances.

The biosynthetic pathway of the cannabinoid producing genetically engineered brewer's yeast (S.
cerevisiae). The genes that encoded for specific enzymes were taken from different origin
organisms and inserted into the yeast genome, in addition to using the organism's own existing
enzymes. The yeast convert sugars and hexanoic acid into the component parts and assemble the
cannabinoid precursor molecule, which is then broken down into different cannabinoids via
different enzymes.
(Fig.1, Luo X., et al., 2019)

Biosynthetic pathways can produce substances that could
potentially be harmful to the survival of a cell in great quantities.
Most biosynthetic pathways have a type of feedback inhibition
built-in to prevent such a fate. In many cases, the final product of
the chain acts to inhibit the first enzyme in the chain by binding to
an allosteric receptor site on the first enzyme. This causes the
active site of the enzyme to change shape and subsequently its
function, stopping or slowing the biosynthetic pathway until
concentration of the final product is low enough that there isn’t
enough of the final product binding to enough of the first enzyme,
at which point the cycle continues and repeats. Even
artificially-created biosynthetic pathways are subject to
feedback-inhibition limits.
Multiple copies of the pathway enzyme genes were introduced to
later strains of yeast produced by the researchers. An increase in
the number of copies of the enzyme showed increases in
concentration of the final product with each additional copy
providing a successively smaller increase in final concentration.
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